PABPC1L

Across TCGA pan-cancer cohorts, PABPC1L mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of PABPC1L’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where PABPC1L mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PABPC1L is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

PDAC, OV, and CCRCC are the cancer types where PABPC1L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PABPC1L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	II,III,IV	−1.255	<.001	8	view →
OV	All	All	+0.515	.044	2	view →
CCRCC	All	II,III,IV	+0.351	.012	2	view →
LUAD	All	II,III,IV	+0.230	.009	2	view →
LSCC	Female	All	+0.680	.016	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

PABPC1L–PDAC

Open the PDAC breakdown →